Yesterday, Sept. 16, 2015, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.69 to $4,488,945.00.

Highlighted Stocks Traded by Insiders:

Misonix (MSON) - FREE Research Report

Zaremba Richard A, who is Senior Vice President and CFO at Misonix, sold 10,000 shares at $10.42 on Sept. 16, 2015. Following this transaction, the Senior Vice President and CFO owned 106,140 shares meaning that the stake was reduced by 8.61% with the 10,000-share transaction.

The shares most recently traded at $10.47, up $0.05, or 0.5% since the insider transaction. Historical insider transactions for Misonix go as follows:

  • 4-Week # shares bought: 100
  • 4-Week # shares sold: 4,186
  • 12-Week # shares bought: 100
  • 12-Week # shares sold: 4,186
  • 24-Week # shares bought: 100
  • 24-Week # shares sold: 7,686

The average volume for Misonix has been 14,700 shares per day over the past 30 days. Misonix has a market cap of $81.3 million and is part of the health care sector and health services industry. Shares are down 14.39% year-to-date as of the close of trading on Wednesday.

Misonix, Inc., a surgical device company, designs, manufactures, and markets therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical applications worldwide. The company has a P/E ratio of 15.9. Currently, there are no analysts who rate Misonix a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MSON - FREE

TheStreet Quant Ratings rates Misonix as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Misonix Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Exponent (EXPO) - FREE Research Report

Johnston Paul R, who is President & CEO at Exponent, sold 5,556 shares at $43.53 on Sept. 16, 2015. Following this transaction, the President & CEO owned 108,650 shares meaning that the stake was reduced by 4.86% with the 5,556-share transaction.

The shares most recently traded at $43.90, up $0.37, or 0.85% since the insider transaction. Historical insider transactions for Exponent go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 19,880
  • 24-Week # shares sold: 28,410

The average volume for Exponent has been 117,000 shares per day over the past 30 days. Exponent has a market cap of $1.1 billion and is part of the services sector and diversified services industry. Shares are up 6.59% year-to-date as of the close of trading on Wednesday.

Exponent, Inc., together with its subsidiaries, provides engineering and scientific consulting services worldwide. It operates in two segments, Engineering and Other Scientific; and Environmental and Health. The stock currently has a dividend yield of 1.37%. The company has a P/E ratio of 28.5. Currently, there is 1 analyst who rates Exponent a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EXPO - FREE

TheStreet Quant Ratings rates Exponent as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Exponent Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

MeetMe (MEET) - FREE Research Report

Cook Geoffrey, who is Chief Executive Officer at MeetMe, sold 30,000 shares at $1.55 on Sept. 16, 2015. Following this transaction, the Chief Executive Officer owned 1.9 million shares meaning that the stake was reduced by 1.54% with the 30,000-share transaction.

The shares most recently traded at $1.69, up $0.14, or 8.31% since the insider transaction. Historical insider transactions for MeetMe go as follows:

  • 4-Week # shares bought: 336,927
  • 4-Week # shares sold: 30,000
  • 12-Week # shares bought: 336,927
  • 12-Week # shares sold: 60,000
  • 24-Week # shares bought: 336,927
  • 24-Week # shares sold: 196,267

The average volume for MeetMe has been 488,600 shares per day over the past 30 days. MeetMe has a market cap of $71.8 million and is part of the technology sector and internet industry. Shares are up 8.5% year-to-date as of the close of trading on Wednesday.

MeetMe, Inc. owns and operates a social network for meeting new people on the Web and on mobile platforms in the United States. The company has a P/E ratio of 22.6. Currently, there is 1 analyst who rates MeetMe a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MEET - FREE

TheStreet Quant Ratings rates MeetMe as a hold. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and revenue growth. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and poor profit margins. Get the full MeetMe Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.